KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Current Assets (2020 - 2025)

Recursion Pharmaceuticals' Current Assets history spans 6 years, with the latest figure at $812.8 million for Q4 2025.

  • For Q4 2025, Current Assets rose 13.8% year-over-year to $812.8 million; the TTM value through Dec 2025 reached $812.8 million, up 13.8%, while the annual FY2025 figure was $812.8 million, 13.8% up from the prior year.
  • Current Assets reached $812.8 million in Q4 2025 per RXRX's latest filing, up from $714.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $812.8 million in Q4 2025 to a low of $221.8 million in Q1 2021.
  • Average Current Assets over 5 years is $537.3 million, with a median of $540.4 million recorded in 2021.
  • Peak YoY movement for Current Assets: surged 179.26% in 2022, then plummeted 30.18% in 2024.
  • A 5-year view of Current Assets shows it stood at $534.7 million in 2021, then increased by 6.56% to $569.8 million in 2022, then fell by 23.11% to $438.1 million in 2023, then soared by 63.02% to $714.3 million in 2024, then grew by 13.8% to $812.8 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Current Assets are $812.8 million (Q4 2025), $714.1 million (Q3 2025), and $587.2 million (Q2 2025).